A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance

Yatan Pal Singh Balhara, Raka Jain, Yatan Pal Singh Balhara, Raka Jain

Abstract

Objectives: To understand the pattern of use of opioid-substitution therapy (OST) and opioid abuse among patients on buprenorphine maintenance using urinalysis.

Materials and methods: The study was conducted at a tertiary care de-addiction center. We reviewed the laboratory record of all consecutive urine samples sent for drug analysis over a period of 1 year. In all, 179 consecutive urine samples were included in the analysis. The chi-square test was used to compare opioid abuse among those testing positive and negative for buprenorphine on urinalysis. Additionally, in order to assess the potential impact of the prescribed induction and maximum dose of buprenorphine on the findings, we carried out the independent-samples t test. Level of statistical significance was kept at P<0.05 for all the tests.

Results: Urinalysis failed to detect buprenorphine in 44.7% of the samples. Rate of detection of dextropropoxyphene was significantly higher among buprenorphine-negative samples (P<0.005). The prescribed induction dose of buprenorphine was significantly lower among those testing positive for heroin. This was found for both buprenorphine-positive (P<0.005) as well as buprenorphine-negative samples (P<0.005).

Conclusions: These findings support the routine use of urine drug screening among individuals on OST.

Keywords: Buprenorphine; opiate substitution therapy; urinalysis.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Findings of urinalysis for the total sample, buprenorphine-positive samples, and buprenorphine-negative samples

References

    1. Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: A three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005;5:452–68.
    1. Muhleisen P, Spence J, Nielsen S. Crushing buprenorphine tablets. Drug Alcohol Rev. 2003;22:471–2.
    1. Tacke U. Abuse of buprenorphine by intravenous injection--the french connection. Addiction. 2002;97:1355.
    1. Reisinger M. Injecting Buprenorphine Tablets: A Manageable Risk. Heroin Addict Relat Clin Probl. 2006;8:29–40.
    1. Jain R, Tripathi BM. Comparison of reported drug use and urinanalysis in the assessment of drug use. The Natl Med J India. 2001;14:176.
    1. Cone EJ, Dickerson SL. Efficacy of urinanalysis in monitoring heroin and cocaine abuse patterns: Implications in clinical trials for treatment of drug dependence. In: Jain RB, editor. Statistical issues in treatment of drug dependence. Washington DC: National Institute on Drug Abuse Research Monograph 128, DHHS Pub. No. (ADM) 92-1947, Supt. Of Docs., US Govt. Print. Off; 1992. pp. 46–58.
    1. Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. DHHS Publication No. (SMA) 04-3939.
    1. NACO. Standard Operating Procedure for Oral Substitution Therapy with Buprenorphine. 2008. [Last accessed 2011 Mar 13]. Available from:
    1. Jain R. Utility of thin layer chromatography for detection of opioids and benzodiazepines in a clinical setting. Addict Behav. 2000;25:451–4.
    1. Jain R. Analytical methods. In: Jain R, editor. Detection of drugs of abuse in body fluids: A manual for laboratory personnel. Drug Dependence Treatment Centre. New Delhi: All India Institute of Medical Sciences; 1998. pp. 18–44.
    1. Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De Chiara M, Corrado F, et al. Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat. 2006;31:3–7.
    1. Gerra G, Borella F, Zaimovic A, Moia G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75:37–45.
    1. Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, et al. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction. 2003;98:1585–97.
    1. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine Use: The International Experience. Clin Infect Dis. 2006;43(Suppl 4):S197–215.
    1. Feroni I, Peretti-Watel P, Paraponaris A, Masut A, Ronfle E, Mabriez JC, et al. French general practitioners’ attitudes and prescription patterns toward buprenorphine maintenance treatment: Does doctor shopping reflect buprenorphine misuse? J Addict Dis. 2005;24:7–22.
    1. Heikman PK, Ojanperä IA. Inadequate Dose of Opioid-agonist Medication is Related to Misuse of Benzodiazepines. Addict Disord Their Treat. 2009;8:45–153.
    1. Doran C, Holmes J, Ladewig D, Ling W. Buprenorphine induction and stabilization in the treatment of opiate dependence. Heroin Addict Relat Clin Probl. 2005;7:7–18.
    1. Di Petta G, Leonardi C. Buprenorphine high-dose, broad spectrum, long-term treatment: A new clinical approach to opiate alkaloid dependency. Heroin Addict Relat Clin Probl. 2005;7:21–5.
    1. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25:79–85.
    1. Collins GB, McAlister MS. Buprenorphine maintenance: A new treatment for opioid dependence. Cleve Clin J Med. 2007;74:514–20.
    1. Johnson RE, Straina EC, Amassb L. Buprenorphine: How to use it right. Drug Alcohol Depend. 2003;70:S59–77.
    1. Stanton A, McLeod C, Kissin W, Sonnefeld J, Luckey J. National Institute on Drug Abuse research monograph series 186. Rockville, MD: US Department of Health and Human Services, National Institutes of Health; 2006. Problems of drug dependence 2005: Proceedings of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence (Orlando) Evaluation of the Buprenorphine Waiver Program: Results from SAMHSA/CSAT's evaluation of the Buprenorphine Waiver Program.
    1. Jain R. Self-reported drug use and urinalysis results. Indian J Physiol Pharmacol. 2004;48:101–5.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit